Adhera Therapeutics Appoints Dr. Andrew Reaume Dr. Reaume is President and CEO of Melior Discovery, Inc., which he co-founded in 2005, building it into a robust, self-sustaining drug discovery organization and leader in pharmaceutical drug repositioning using the unique theraTRACE® platform comprised of multiplexed in vivo disease models. He subsequently spun off two sister companies, Melior Pharmaceuticals I, Inc., Melior Pharmaceuticals II, LLC, for the purpose of developing proprietary clinical stage drug candidates.
Dr. Reaume has been responsible for raising over $15 million of investment capital for the Melior businesses and completed over $40 million in partnering deals, including research partnerships with global pharmaceutical companies. He was responsible for spearheading and continues to oversee a complex global development partnership with an Asian pharmaceutical partner.
Prior to Melior, Dr. Reaume held leadership roles in drug discovery and business analytics at NYSE-listed Pfizer and NASDAQ-listed Cephalon, which was acquired in 2011 by Teva Pharmaceuticals for $6.8 billion. In aggregate, he has more than twenty-five years of experience in the pharmaceutical industry. He received his MBA from the Wharton School of the University of Pennsylvania where he graduated with honors in Entrepreneurial Management. He received his PhD in genetics from the University of Connecticut.
https://www.globenewswire.com/news-release/2021/09/09/2294464/0/en/Adhera-Therapeutics-Appoints-Dr-Andrew-Reaume-to-Board-of-Directors.html